A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

NCT05150691 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

796

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-positive Advanced Solid Tumor

Interventions

BIOLOGICAL: DB-1303/BNT323
DRUG: Pertuzumab Injection
DRUG: Ritonavir
DRUG: Itraconazole

Sponsor

DualityBio Inc.

Collaborators

[object Object]